Published
Reclast is still not on the market,from what I heard on the TV news this week. According to what I heard, it should be at least the end of the year before it is available. It will be a "15 minute once a year IV infusion." However, Boniva is a once a month oral preparation, and if I remember correctly, Fosamax is once weekly. The question was in reference to Boniva and Fosamax. I work in a cardiology practice. We have two Cardiologists who specialize in electrophysiology (EP). I've never heard of the Boniva-Fosamax connection with atrial fib, but anything is possible. I'll check it out with our EP docs and let you all know what they say.
This link is a pharma blog, but it does reference the medical journal that this was discussed in.(you need to subscribe to see the medical journal)
http://pharmalot.com/2007/05/osteoporosis_drugs_tied_to_irr.php
OK - One perk as a student is I have access to many online journals. I just spend a long time reading NEJM looking for information on this.
The first study cited was for zoledronic acid (AKA Reclast or Zometa). It is a once-yearly IV injection for post-menopausal women to prevent osteoporosis. 3889 women received the med and 3876 did not. They received the infusions at baseline, at 12 months, at 24 months, and at 36 months. Of those that received the med, 50 (1.3%) had an event of serious a-fib and of the placebo group 20 (0.5%) had an event of serious a-fib. A serious a-fib event was defined as resulting in hospitalization or disability or life threatening. Although the occurences are low, the treatment group's occurences of serious a-fib events was significantly higher (statistically speaking). There was not, however, an increased risk of all adverse effects of a-fib...considering all occurences of a-fib, there were 94 (2.4%) events in the treatment group and 73 (1.9%) events in the placebo group
The other article is about the occurences of a-fib in a previous study done on alendronate (Fosamax). That study involved 6459 post-menopausal women and spanned 4 years. The final report provided to the FDA in 1997 showed there were 47 (1.5%) serious a-fib events for those taking Fosamax compared to 31 (1.0%) on placebo. The difference wasn't statistically significant. The risk for all a-fib events was 81 (2.5%) versus 71 (2.2%), also not considered statistically significant. So, it was suggested that a-fib would not be a major adverse effect of taking Fosamax.
Nothing is mentioned about Boniva in this issue.
passing thru
655 Posts
Has anyone been hearing anything about these drugs having the side effect , a rather common side effect it seems, of a- fib ??
I saw something about it on t.v. , but wasn't able to watch the full program.